Navigation Links
Microbix' Pipeline Set To Reach Milestones In 2010
Date:12/16/2009

e compared with a loss of $440,113 or 1 cent a share in 2008. Cash flow was negative for both the quarter and full year compared to slightly positive in 2008.

In September, Microbix raised $750,000 in equity through a brokered private placement financing with significant high net-worth investor participation. The funds are being used for working capital.

The development of the Hunan Joint Venture and extensive business development activities associated with concluding agreements for the Urokinase acquisition increased the loss this year. Microbix has undergone a corporate restructuring to conserve resources and lower its cash burn rate in order to ensure its pipeline products reach their full potential. Microbix is expected to turn cash flow positive in 2010.

                            Quarter Ended Sept 30      Year Ended Sept 30
                              2009         2008         2009         2008
                          ---------------------------------------------------

    Revenue               $ 1,514,306    1,259,749    6,082,469    4,993,521

    Net Income (Loss)     $  (715,667)    (440,113)  (2,484,535)  (3,667,909)

    Net Income (Loss)
     per share            $     (0.01)       (0.01)       (0.05)       (0.08)

    Cash Flow             $  (185,750)      17,914   (2,819,490)   2,769,660


    About Microbix
    --------------

Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to ge
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
6. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
7. Microbix Sales Grow 22% For Nine Months
8. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
9. Microbix Biosystems Provides a Corporate Update
10. Microbix Biosystems Re-files Annual Results With OSC
11. Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... , December 23, 2014 PharmaBoardroom,s ... , out today and available for free download , ... driving change and growth in the sector today. ... notable successes has been in developing a homegrown pharmaceutical manufacturing ... local production still remains some way off. A cursory comparison ...
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Network,s 3-Minute,Press Show is a daily program hosted by ... company executives on their,company and most recent press releases., ... insight into a company,s,latest news, and its impact on ... Monday through Friday at: http://tv.wallst.net/3-min-press/3-min-press.php , ...
... Gaining a first-cycle,approval for a new molecular ... incremental revenue on average, according to a new ... International (Nasdaq: PRXL ),and leading global life ... According to the PAREXEL Consulting,analysis, 60 percent of ...
... DC The future of how the world ... likely come from the same source: nanotechnology. According ... the Project on Emerging Nanotechnologies (PEN), nanotechnology will ... electronics and "green" energy technologies. , In ...
Cached Biology Technology:[video] Wall St. Network's 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... during the Oligocene epoch, some 33.6 million years ago, ... the Andalusian Institute of Earth Sciences (IACT)a Spanish National ... on information contained in ice sediments from different depths, ... ., Before the ice covered Antarctica, the Earth was ...
... a world-leading provider of scientific, technical and medical ... the launch of Translational Proteomics , an ... discoveries in the field of proteomics to clinical ... Jean-Charles Sanchez, Associate Professor at the University ...
... at UC Irvine reported this week that a synthetic compound ... found to enhance metabolic activity and shows potential as a ... published the week of May 27 in the Proceedings ... selectively blocks the activity of a protein that promotes inflammation ...
Cached Biology News:The Antarctic polar icecap is 33.6 million years old 2UCI researchers find sea anemone venom-derived compound effective in anti-obesity studies 2UCI researchers find sea anemone venom-derived compound effective in anti-obesity studies 3
Mouse Cell Line Slides...
Request Info...
Human Cell Line Slides...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
Biology Products: